Subcutaneous medetomidine-vatinoxan-butorphanol produced sedation adequate for orthopedic radiography in healthy dogs, but only at doses higher than the intramuscular standard, according to a randomized, controlled dose-finding study published October 6, 2026, in The Veterinary Journal (DOI: 10.1016/j.tvjl.2026.106921).

Fifty-three privately-owned, healthy dogs were randomly assigned to one of five treatment arms. Two received intramuscular injections: medetomidine 0.6 mg/m² alone (M0.6-IM) and medetomidine/vatinoxan at 0.6/12 mg/m² (Z0.6-IM). Three received the medetomidine/vatinoxan combination subcutaneously at escalating doses: 0.6/12 (Z0.6-SC), 0.9/18 (Z0.9-SC) and 1.2/24 mg/m² (Z1.2-SC). Every protocol included butorphanol at 0.2 mg/kg.

What does the route change at the exam table?

The route changed two things practitioners will care about: onset time and dose requirements. Sedation occurred earlier after both IM treatments than after any of the SC treatments.

The subcutaneous route also appeared less potent. Rescue sedation to complete radiography tracked inversely with the SC dose:

• Z0.6-SC: 4 of 11 dogs needed rescue
• Z0.9-SC: 2 of 10
• Z1.2-SC: 1 of 10
• Z0.6-IM: 0 of 11
• M0.6-IM: 1 of 11

In practical terms, the SC route delivered comparable sedation to IM only after the medetomidine-vatinoxan dose was pushed to roughly 1.5 to 2 times the IM dose. For dogs that tolerate IM injection poorly — a real constraint in anxious or fractious patients — the authors note SC administration may be better tolerated, and this trial quantifies the dosing price of that choice.

Did vatinoxan protect circulation?

It did, and regardless of route. The study measured oral mucosal microcirculation with Laser Doppler Flow (LDF) and tissue hemoglobin saturation (T-HbO₂), alongside mean arterial pressure (MAP) and heart rate.

After plain IM medetomidine (M0.6-IM), median LDF was 55 perfusion units (range 36–113) and median T-HbO₂ was 64% (range 49–79%). Every vatinoxan-containing protocol, IM or SC, produced significantly higher values:

• Z0.6-IM: 155 PU (105–312); 81% (67–87%)
• Z0.9-SC: 196 PU (126–492); 79% (72–94%)
• Z0.6-SC (reported in the Z0.9-SC position of the published abstract): 163 PU (68–465); 77% (72–84%)
• Z1.2-SC: 146 PU (82–422); 77% (69–85%)

The differences between the vatinoxan treatments were not significant. That finding extends the known peripheral α1-antagonist effect of vatinoxan on medetomidine-induced vasoconstriction to subcutaneous co-administration with butorphanol.

Heart rate fell significantly from baseline after all five treatments. Hypotension, defined as MAP below 60 mmHg, was not observed in any dog.

How should clinicians read the evidence?

Three caveats frame the clinical take-home. The dogs were healthy, so the results do not transfer directly to patients with cardiovascular or systemic disease. The endpoint was sedation for orthopedic radiography, a moderate procedural target, not anesthesia or major intervention. And the trial was designed for dose-finding, with roughly ten dogs per arm, so the rescue-sedation figures carry wide confidence.

The study is open access under a Creative Commons license and appears as an in-press journal pre-proof from Elsevier. Vatinoxan (also known as MK-467) is not approved by the FDA CVM in a marketed sedation combination for dogs in the United States; the compound has been studied in registered European fixed-combination products, and practitioners should check current regulatory status in their jurisdiction before extrapolating these dose ratios.

The investigators conclude that subcutaneously administered medetomidine-vatinoxan-butorphanol appeared efficacious, albeit less potent than the IM route, in healthy dogs — and that the hemodynamic benefit of vatinoxan persisted with SC delivery. Larger trials in patient populations with comorbidities will determine whether the subcutaneous route earns a place in everyday sedation protocols.